A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

According to Liu, his preferred option is faricimab, a fairly new agent that was FDA-approved for wet AMD in 2022. The drug ...

Discover Harrow Inc.'s growth strategy, bullish long-term prospects, and Q3 earnings outlook in ophthalmology. Click for more on HROW stock ahead of earnings.

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the, Inc. (Melt), a clinical-stage pharmaceutical company ...

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition affects the back of the eye where light is processed by ...

Around a third of people over the age of 80 suffer from age-related macular degeneration (AMD), with an estimated 20 million Americans aged 40 and older currently living with AMD. Most cases are the ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

A laser treatment for this common eye disease will start clinical trials in Finland next spring ––researchers hope it could be available to sufferers in as little as three years Around a third of ...